Millennium Pharmaceuticals Limited

Other

Enanta Pharmaceuticals, Inc.

Millenium Pharmaceuticals, Inc.

Eric L Elliott

Quentin J McCubbin

Debra L Mazaik

Phuong Nguyen

Raymond D Skwierczynski

Nobel T Truong

Michael J Kaufman

Vaithianathan Palaniappan

Csanad M Varga

Abu J Ferdous

Marianne Langston

Peter Zawaneh

Quentin J Mccubbin

Steven P Langston

Lei Zhu

Ian G Armitage

Matthew Stirling

Sonja A Komar-Lay

Sonja A Komar

Hiro Mizutani

Peter N Zawaneh

Yat Sun Or

Zhe Wang

Patricia Andres

Joel D Moore

Hirotake Mizutani

Jing Teng

Anton Peterson

Phoung M Nguyen

Sonja A Komar Lay

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Boronate ester compounds and pharmaceutical compositions thereof

The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity. 

Process for the synthesis of E1 activating enzyme inhibitors

The present disclosure relates to a novel crystalline form of a proteasome inhibitor, and to the processes for the preparation thereof. The novel crystalline form according to the disclosure may be used in the preparation of pharmaceutical compositions for the treatment of cancer.

Crystalline form of a proteasome inhibitor

The present invention provides sulfamoylating reagents of formula RN&#x2014;S(O)X, wherein X is a cyclic tertiary amine or a nitrogen-containing heteroaryl and Ris an amine protecting group or hydrogen.

Sulfamoylating reagents

Disclosed are processes and synthetic intermediates for the synthesis of compounds of formula (V) wherein the variables have the definitions contained herein. Such compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity. 

The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. 

Hydrazide-containing hepatitis C serine protease inhibitors

Growing community of inventors

Brighton, MA, United States of America

Eric L Elliott